Zynerba Pharmaceuticals Stock Forecast, Price & News

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Frequently Asked Questions

Is Zynerba Pharmaceuticals a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zynerba Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Zynerba Pharmaceuticals stock.
View analyst ratings for Zynerba Pharmaceuticals or view top-rated stocks.

How has Zynerba Pharmaceuticals' stock been impacted by Coronavirus?

Zynerba Pharmaceuticals' stock was trading at $3.89 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ZYNE shares have decreased by 37.0% and is now trading at $2.45.
View which stocks have been most impacted by COVID-19.

When is Zynerba Pharmaceuticals' next earnings date?

Zynerba Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, March 9th 2022.
View our earnings forecast for Zynerba Pharmaceuticals.

How were Zynerba Pharmaceuticals' earnings last quarter?

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) issued its quarterly earnings data on Monday, November, 15th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.01.
View Zynerba Pharmaceuticals' earnings history.

What price target have analysts set for ZYNE?

4 brokerages have issued 1-year price targets for Zynerba Pharmaceuticals' shares. Their forecasts range from $7.25 to $9.00. On average, they anticipate Zynerba Pharmaceuticals' share price to reach $8.08 in the next twelve months. This suggests a possible upside of 229.9% from the stock's current price.
View analysts' price targets for Zynerba Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Zynerba Pharmaceuticals' key executives?

Zynerba Pharmaceuticals' management team includes the following people:

• Armando Anido, Chairman & Chief Executive Officer
• Terri B. Sebree, President
• James E. Fickenscher, Chief Financial Officer & VP-Corporate Development
• Nancy Tich, Vice President-Clinical
• Suzanne M. Hanlon, Secretary, Vice President & General Counsel

Who are some of Zynerba Pharmaceuticals' key competitors?

Some companies that are related to Zynerba Pharmaceuticals include CytoDyn (CYDY), Verona Pharma (VRNA), Theseus Pharmaceuticals (THRX), Oramed Pharmaceuticals (ORMP), Allakos (ALLK), Marinus Pharmaceuticals (MRNS), G1 Therapeutics (GTHX), ESSA Pharma (EPIX), Rigel Pharmaceuticals (RIGL), Avadel Pharmaceuticals (AVDL), Generation Bio (GBIO), Nkarta (NKTX), Xilio Therapeutics (XLO), Akebia Therapeutics (AKBA) and Nature's Sunshine Products (NATR).
View all of ZYNE's competitors.

What other stocks do shareholders of Zynerba Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zynerba Pharmaceuticals investors own include (CGC), Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), Cronos Group (CRON), Aurora Cannabis (ACB), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Shopify (SHOP) and Micron Technology (MU).

When did Zynerba Pharmaceuticals IPO?

(ZYNE) raised $42 million in an IPO on Wednesday, August 5th 2015. The company issued 3,000,000 shares at $13.00-$15.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers.

What is Zynerba Pharmaceuticals' stock symbol?

Zynerba Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZYNE."

Who are Zynerba Pharmaceuticals' major shareholders?

Zynerba Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Cutler Group LP (0.00%).
View institutional ownership trends for Zynerba Pharmaceuticals.

How do I buy shares of Zynerba Pharmaceuticals?

Shares of ZYNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zynerba Pharmaceuticals' stock price today?

One share of ZYNE stock can currently be purchased for approximately $2.45.

How much money does Zynerba Pharmaceuticals make?

Zynerba Pharmaceuticals has a market capitalization of $100.98 million. The company earns $-51.34 million in net income (profit) each year or ($1.04) on an earnings per share basis.

How many employees does Zynerba Pharmaceuticals have?

Zynerba Pharmaceuticals employs 26 workers across the globe.

What is Zynerba Pharmaceuticals' official website?

The official website for Zynerba Pharmaceuticals is www.zynerba.com.

Where are Zynerba Pharmaceuticals' headquarters?

Zynerba Pharmaceuticals is headquartered at 80 W. LANCASTER AVENUE SUITE 300, DEVON PA, 19333.

How can I contact Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals' mailing address is 80 W. LANCASTER AVENUE SUITE 300, DEVON PA, 19333. The company can be reached via phone at (484) 581-7505 or via email at [email protected].